Karyopharm Therapeutics Inc (KPTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.79+1.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KPTI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Submit supplemental New Drug Application (sNDA) for selinexor plus ruxolitinib in myelofibrosis under Accelerated Approval pathway and seek Priority Review.
Stated as a priority in 2 of last 2 quarters. Management confirmed the planned sNDA submission for selinexor plus ruxolitinib in myelofibrosis under the Accelerated Approval pathway in August 2026. This follows positive Phase 3 SENTRY trial results and ongoing FDA engagement. The trajectory is delivering as the company remains on track for the regulatory milestone.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Company remains on track to submit planned sNDA in August under Accelerated Approval pathway for selinexor plus ruxolitinib in myelofibrosis.”
“Engage with FDA on data from SENTRY trial and sNDA filing plan; potential inclusion in compendia in second half of 2026.”
Grow U.S. net product revenue for XPOVIO amid competitive multiple myeloma market and support global launches.
Stated as a priority in 2 of last 2 quarters. U.S. XPOVIO net product revenue increased from $29.7 million in 2025-Q2 to $30.8 million in 2026-Q2, showing modest growth amid a competitive market. The company also reported growth from $21.1 million in 2025-Q1 to $29.2 million in 2026-Q1. Management continues to emphasize revenue growth and global launch support, indicating delivery on this priority.
“U.S. net product revenue was $30.8 million for Q2 2026 compared to $29.7 million for Q2 2025.”
“U.S. net product revenue was $29.2 million for Q1 2026 compared to $21.1 million for Q1 2025.”
Maintain disciplined spending on research and development and selling, general and administrative expenses to improve operating efficiency.
Stated as a priority in 2 of last 2 quarters. R&D expenses decreased from $32.8 million in 2025-Q2 to $29.0 million in 2026-Q2, and SG&A expenses decreased from $28.5 million to $25.9 million over the same period. Management's focus on cost discipline and efficient spending is reflected in these reductions, indicating progress on this priority.
“R&D expenses were $29.0 million and SG&A expenses were $25.9 million in Q2 2026, down from prior year.”
“R&D expenses were $33.8 million and SG&A expenses were $26.7 million in Q1 2026, reflecting disciplined cost management.”
Actively pursue financing options and strategic alternatives to extend cash runway and preserve flexibility for advancing myelofibrosis program.
Stated as a priority in 2 of last 2 quarters. The company reported cash, cash equivalents, and investments of $91.2 million at 2026-Q1 and $65.4 million at 2026-Q2, reflecting cash burn. Management is actively evaluating financing opportunities and strategic alternatives to extend the cash runway and preserve flexibility, indicating ongoing focus but limited progress on extending liquidity so far.
“Company is actively evaluating financing opportunities and strategic alternatives to extend cash runway and preserve flexibility.”
“Company expects existing liquidity and cash flow to fund operations into late Q3 2026; evaluating financing options.”
Continue efforts to manage and reduce operating expenses to improve financial performance.
Over the trailing year it converted 0.99x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.